Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05979922 · ClinicalTrials.gov registry record · Phase 2
Mindfulness-based Cognitive Coping for ADRD Caregivers
A Phase 2 study, sponsored by Photozig.
- Completed
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
NCT05979922: Completed Phase 2 study, sponsored by Photozig.
NCT05979922 is a Phase 2 study that has completed, run by Photozig. The registered enrollment target is 174 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05979922, a Phase 2 study, has completed, sponsored by Photozig.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
Study Summary
This project will evaluate the effectiveness of the Mindfulness-based Cognitive Coping (MCC) intervention to alleviate stress and depressive symptoms of caregivers of Individuals with Alzheimer's Disease and Related Dementia.
Primary Outcome
The Center for Epidemiological Studies Depression scale (CES-D) is a 20-item measure that asks about the frequency of depressive symptoms (affective, psychological, and somatic) within the past week.The scale refers to the caregiver. Minimum score (best value)=0. Maximum score (worst value)=60. Higher values represent a worse outcome.
Interventions
- BEHAVIORAL Traditional Educational/Resources Program
- BEHAVIORAL Mindfulness-based Cognitive Coping
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2023-07-27 |
| Est. Completion | 2024-06-17 |
| Phase | Phase 2 |
What the finished NCT05979922 record still lists
NCT05979922 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% higher).
The record links to 0 conditions, and to 2 interventions - of which Traditional Educational/Resources Program is the first listed.
NCT05979922 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05979922 about?
NCT05979922 is a clinical study titled "Mindfulness-based Cognitive Coping for ADRD Caregivers". This project will evaluate the effectiveness of the Mindfulness-based Cognitive Coping (MCC) intervention to alleviate stress and depressive symptoms of caregivers of Individuals with Alzheimer's Disease and Related Dementia.
What is the current status of trial NCT05979922?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2023-07-27. Estimated completion is 2024-06-17.
What interventions are being tested in trial NCT05979922?
The interventions under investigation include: Traditional Educational/Resources Program (BEHAVIORAL), Mindfulness-based Cognitive Coping (BEHAVIORAL).
Who is sponsoring clinical trial NCT05979922?
This trial is sponsored by Photozig, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05979922's enrollment target sits among peer trials
174 396th of 2000 higher than 1,604 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI